Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Receivables (2016 - 2024)

Dare Bioscience's Receivables history spans 9 years, with the latest figure at $929982.0 for Q4 2024.

  • For Q4 2024, Receivables changed N/A year-over-year to $929982.0; the TTM value through Dec 2024 reached $929982.0, changed N/A, while the annual FY2024 figure was $929982.0, N/A changed from the prior year.
  • Receivables reached $929982.0 in Q4 2024 per DARE's latest filing, down from $12.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $52.0 million in Q2 2021 to a low of $282560.0 in Q3 2020.
  • Average Receivables over 4 years is $8.5 million, with a median of $893852.0 recorded in 2020.
  • Peak YoY movement for Receivables: surged 14997.48% in 2021, then tumbled 76.64% in 2022.
  • A 4-year view of Receivables shows it stood at $472168.0 in 2020, then skyrocketed by 142.57% to $1.1 million in 2021, then surged by 959.76% to $12.1 million in 2022, then crashed by 92.34% to $929982.0 in 2024.
  • Per Business Quant, the three most recent readings for DARE's Receivables are $929982.0 (Q4 2024), $12.1 million (Q2 2022), and $1.1 million (Q4 2021).